quizartinib
Two Daiichi Sankyo drugs dealt a thumbs up and thumbs down by FDA advisory panel
May 15, 2019Research and Development, Sales and Marketing Daiichi Sankyo, FDA, pexidartinib, pharma, quizartinib
Daiichi Sankyo was left with a bittersweet taste in its mouth after it saw one of its drugs recommended for …
Daiichi Sankyo pays $410m for Ambit Biosciences
September 29, 2014Sales and Marketing AML, Daiichi Sankyo, ambit biosciences, quizartinib
Daiichi Sankyo has bought San Diego-based Ambit Biosciences in a deal aimed at shoring up the Japanese company’s cancer research. …
Latest content
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
AI: an early warning system for patient safety
November 3, 2026
Highlighting the value of lab research for healthcare innovation
November 2, 2026
